Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Imatinib . mesylate

Tyrosine kinase inhibitor
ALX-270-492-M025 25 mg 52.00 USD
ALX-270-492-M100 100 mg 142.00 USD
ALX-270-492-M500 500 mg 512.00 USD
Do you need bulk/larger quantities?
Tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). Also shown to inhibit the transmembrane receptor kit and platelet-derived growth factor (PDGF) receptors.

Product Details

Alternative Name:STI-571, CGP-57148B
Formula:C29H31N7O . CH3SO3H
MW:493.6 . 96.1
MI:14: 4902
Purity:≥98% (HPLC)
Appearance:White to pale yellow crystalline powder.
Solubility:Soluble in water (200mg/ml) or DMSO (100mg/ml) or DMF (10mg/ml) or PBS (2mg/ml). Sparingly soluble in ethanol (0.2mg/ml). Storing aqueous solutions for more than one day is not recommended.
Shipping:Ambient Temperature
Long Term Storage:+4°C
Regulatory Status:RUO - Research Use Only
Please mouse over

Product Literature References

An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17- prostacyclin signalling axis: A.J. Ainscough, et al.; Commun. Biol. 5, s42003 (2023), Abstract;
An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17-prostacyclin signalling axis: A.J. Ainscough, et al.; Commun. Biol. 5, 1192 (2022), Abstract;
Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanoma: I. Berestjuk, et al.; EMBO Mol. Med. 14, e11814 (2022), Abstract;
Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models: F. Muselli, et al.; Cancers 13, 1693 (2021), Abstract; Full Text
Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials: C.J. Korbee, et al.; Nat. Commun. 9, 358 (2018), Abstract; Full Text
Direct modification of the 5-HT3 receptor current by some anticancer drugs: Y. Nakamura, et al.; Eur. J. Pharmacol. 821, 21 (2017), Abstract;
Importance of pulmonary vein preferential fibrosis for atrial fibrillation promotion in hypertensive rat hearts: Y. Iwasaki, et al.; Can. J. Cardiol. 32, 767 (2016), Application(s): Cell Culture, Abstract;
Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling: M.T. Weigel, et al.; Cancer Lett. 273, 70 (2009), Abstract;
Imatinib as a novel therapeutic approach for fibrotic disorders: J.H. Distler & O. Distler; Rheumatology (Oxford) 48, 2 (2009), Abstract;
Imatinib mesylate for the treatment of chronic myeloid leukemia: S. Soverini, et al.; Expert Rev. Anticancer Ther. 8, 853 (2008), (Review), Abstract;
Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors?: F. Miselli, et al.; Transl. Oncol. 1, 177 (2008), Abstract;
Imatinib: C.E. de Kogel & J.H. Schellens; Oncologist 12, 1390 (2007), (Review), Abstract;
The kinase inhibitor imatinib--an immunosuppressive drug?: D. Wolf, et al.; Cancer Drug Targets 7, 251 (2007), (Review), Abstract;
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors: E. Buchdunger, et al.; J. Pharmacol. Exp. Ther. 295, 139 (2000), Abstract;
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative: E. Buchdunger, et al.; Cancer Res. 56, 100 (1996), Abstract;

Product Toolbox


Certificate of Analysis


By target:
PDGF receptor
By biological activity:
Abl Inhibitor
PDGF receptor Inhibitor
By catalog section:


Technical Service
Customer Service